{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:36:39Z","timestamp":1740108999602,"version":"3.37.3"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T00:00:00Z","timestamp":1727913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To assess the impact of differences in Prostate-Specific Antigen (PSA) testing rates on prostate cancer (PCa) diagnosis and PCa-specific mortality among M\u0101ori men in a New Zealand (NZ) population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>M\u0101ori men aged 40 years or older, without a history of PCa, with a PSA test between 2006 and 2018 were included. The cohort was divided into two groups; the \u201cscreened group\u201d (ScG) consisting of men who had at least one PSA test every four years or less, and the \u201cnon-screened group\u201d (non-SG). We measured the rate of cancer diagnoses and used competing risk analysis to assess survival.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The study cohort included 63,939 M\u0101ori men, with 37,048 (58%) in the ScG. PCa was more frequently diagnosed in the ScG (3.7% vs. 3.0%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). A higher proportion of high-grade cancers were found in the non-SG (32.7% vs. 25.6%, <jats:italic>P<\/jats:italic>\u2009=\u20090.001). The 10-year cancer-specific survival was significantly higher in the ScG (99.4% vs. 98.5%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). In a multivariable risk model, PSA testing frequency was an independent predictor of PCa mortality. (HR 2.43, [95% CI 1.97\u20133.01], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In a cohort of only M\u0101ori men, lower PSA testing rates were associated with a higher risk of PCa-related death. Therefore, regular PSA testing for M\u0101ori could improve cancer-specific survival among M\u0101ori men. Regular PSA testing should be considered a priority area for improving PCa survival in this population.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-024-05260-2","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T11:02:27Z","timestamp":1727953347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The impact of non-structured PSA testing on prostate cancer-specific mortality on New Zealand M\u0101ori men"],"prefix":"10.1007","volume":"42","author":[{"given":"Bashar","family":"Matti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy H.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mataroria P.","family":"Lyndon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kamran","family":"Zargar-Shoshtari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,3]]},"reference":[{"issue":"12","key":"5260_CR1","doi-asserted-by":"publisher","first-page":"2806","DOI":"10.1111\/ans.17263","volume":"91","author":"B Matti","year":"2021","unstructured":"Matti B, Chapman D, Zargar-Shoshtari K (2021) Ethnic and regional differences in the temporal trends of prostate cancer incidence and mortality in New Zealand. ANZ J Surg 91(12):2806\u20132816","journal-title":"ANZ J Surg"},{"issue":"5","key":"5260_CR2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.urolonc.2019.12.009","volume":"38","author":"B Matti","year":"2020","unstructured":"Matti B, Zargar-Shoshtari K (2020) Opportunistic prostate cancer screening: a population-based analysis. Urol Oncol 38(5):393\u2013400","journal-title":"Urol Oncol"},{"issue":"1","key":"5260_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.eururo.2019.02.009","volume":"76","author":"J Hugosson","year":"2019","unstructured":"Hugosson J, Roobol MJ, Mansson M, Tammela TLJ, Zappa M, Nelen V et al (2019) A 16-yr follow-up of the European randomized study of screening for prostate Cancer. Eur Urol 76(1):43\u201351","journal-title":"Eur Urol"},{"issue":"4","key":"5260_CR4","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/pcan.2017.32","volume":"20","author":"KA Moses","year":"2017","unstructured":"Moses KA, Zhao Z, Bi Y, Acquaye J, Holmes A, Blot WJ et al (2017) The impact of sociodemographic factors and PSA screening among low-income Black and White men: data from the Southern Community Cohort Study. Prostate Cancer Prostatic Dis 20(4):424\u2013429","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"5260_CR5","volume-title":"NZDep2013 index of deprivation","author":"J Atkinson","year":"2014","unstructured":"Atkinson J, Salmond C, Crampton P (2014) NZDep2013 index of deprivation. Department of Public Health, University of Otago, Wellington"},{"issue":"9959","key":"5260_CR6","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"FH Schr\u00f6der","year":"2014","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V et al (2014) Screening and prostate cancer mortality: results of the European Randomised study of screening for prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959):2027\u20132035","journal-title":"Lancet"},{"issue":"Suppl 3","key":"5260_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bju.15155","volume":"128","author":"B Matti","year":"2021","unstructured":"Matti B, Lyndon M, Zargar-Shoshtari K (2021) Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand. BJU Int 128(Suppl 3):11\u201317","journal-title":"BJU Int"},{"issue":"6","key":"5260_CR8","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.urolonc.2021.02.023","volume":"39","author":"B Matti","year":"2021","unstructured":"Matti B, Zargar-Shoshtari K (2021) Prostate cancer outcomes disparities: Population survival analysis in an ethnically diverse nation. Urol Oncol 39(6):367 e19- e26","journal-title":"Urol Oncol"},{"issue":"10","key":"5260_CR9","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1093\/aje\/kww084","volume":"184","author":"TP Kilpelainen","year":"2016","unstructured":"Kilpelainen TP, Talala K, Raitanen J, Taari K, Kujala P, Tammela TLJ et al (2016) Prostate Cancer and socioeconomic status in the Finnish randomized study of screening for prostate Cancer. Am J Epidemiol 184(10):720\u2013731","journal-title":"Am J Epidemiol"},{"issue":"12","key":"5260_CR10","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1002\/ijc.31272","volume":"142","author":"K Tomic","year":"2018","unstructured":"Tomic K, Ventimiglia E, Robinson D, Haggstrom C, Lambe M, Stattin P (2018) Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer 142(12):2478\u20132484","journal-title":"Int J Cancer"},{"issue":"2","key":"5260_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1158\/1078-0432.CCR-18-1807","volume":"25","author":"T Pakarainen","year":"2019","unstructured":"Pakarainen T, Nevalainen J, Talala K, Taari K, Raitanen J, Kujala P et al (2019) The number of screening cycles needed to reduce prostate Cancer mortality in the Finnish section of the European Randomized study of prostate Cancer (ERSPC). Clin Cancer Res 25(2):839\u2013843","journal-title":"Clin Cancer Res"},{"issue":"9","key":"5260_CR12","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1001\/jama.2018.0154","volume":"319","author":"RM Martin","year":"2018","unstructured":"Martin RM, Donovan JL, Turner EL, Metcalfe C, Young GJ, Walsh EI et al (2018) Effect of a low-intensity PSA-Based screening intervention on prostate Cancer mortality: the CAP Randomized Clinical Trial. JAMA 319(9):883\u2013895","journal-title":"JAMA"},{"key":"5260_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/bju.15155","volume":"128","author":"B Matti","year":"2021","unstructured":"Matti B, Lyndon M, Zargar-Shoshtari K (2021) Ethnic and socio\u2010economic disparities in prostate cancer screening: lessons from New Zealand. BJU Int 128:11\u201317","journal-title":"BJU Int"},{"issue":"18","key":"5260_CR14","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1001\/jama.2018.3712","volume":"319","author":"JJ Fenton","year":"2018","unstructured":"Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J (2018) Prostate-specific antigen\u2013based screening for prostate cancer: evidence report and systematic review for the US Preventive Services Task Force. JAMA 319(18):1914\u20131931","journal-title":"JAMA"},{"issue":"13","key":"5260_CR15","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","volume":"360","author":"FH Schr\u00f6der","year":"2009","unstructured":"Schr\u00f6der FH, Hugosson J, Roobol MJ, Tammela TLJ, Ciatto S, Nelen V et al (2009) Screening and prostate-Cancer mortality in a randomized European study. N Engl J Med 360(13):1320\u20131328","journal-title":"N Engl J Med"},{"issue":"1","key":"5260_CR16","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41585-019-0212-4","volume":"17","author":"A Stabile","year":"2020","unstructured":"Stabile A, Giganti F, Rosenkrantz AB, Taneja SS, Villeirs G, Gill IS et al (2020) Multiparametric MRI for prostate cancer diagnosis: current status and future directions. Nat Reviews Urol 17(1):41\u201361","journal-title":"Nat Reviews Urol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05260-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-024-05260-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-024-05260-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T21:23:28Z","timestamp":1735853008000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-024-05260-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5260"],"URL":"https:\/\/doi.org\/10.1007\/s00345-024-05260-2","relation":{},"ISSN":["1433-8726"],"issn-type":[{"type":"electronic","value":"1433-8726"}],"subject":[],"published":{"date-parts":[[2024,10,3]]},"assertion":[{"value":"17 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Health and Disability Ethics Committee (HDEC reference number 17\/CEN\/239). No informed consent was required in this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Nil.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"558"}}